A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine

In this extension study, V59P20E1, the sponsor was planning to assess 5-year antibody persistence in subjects who received one or two doses of MenACWY conjugate vaccine at 2 to 10 years of age, and to evaluate response to a booster dose administered 5 years after primary vaccination in the parent study V59P20 (NCT00616421).

本延伸性研究V59P20E1中，申办方拟评估2至10岁年龄段接种1剂或2剂ACYW135群脑膜炎球菌结合疫苗（MenACWY conjugate vaccine）的受试者的5年抗体持久性，并评估受试者在母体研究V59P20（NCT00616421）完成基础免疫后5年时接受加强针的免疫应答情况。